Autor: |
Jerkeman, Mats, Eskelund, Christian Winther, Hutchings, Martin, Räty, Riikka, Wader, Karin Fahl, Laurell, Anna, Toldbod, Helle, Pedersen, Lone Bredo, Niemann, Carsten Utoft, Dahl, Christina, Kuitunen, Hanne, Geisler, Christian H, Grønbæk, Kirsten, Kolstad, Arne |
Zdroj: |
The Lancet Haematology; March 2018, Vol. 5 Issue: 3 pe109-e116, 8p |
Abstrakt: |
Regimens based on ibrutinib alone and lenalidomide and rituximab in combination show high activity in patients with relapsed or refractory mantle cell lymphoma. We hypothesised that the combination of all three drugs would improve efficacy compared with previously published data on either regimen alone. |
Databáze: |
Supplemental Index |
Externí odkaz: |
|